GlassScriptPhysician profile
Emily Sue Essendrup
NPI 1295494516
$2,853.53
in general payments reported to CMS, 2019-2025
36 companies · $660 in 2025
The $660 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $373 · 2023: $1,132 · 2024: $688 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.48 |
| Education | $283.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $519.21 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $237.84 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $231.58 | 2022-2025 | Kisqali, Piqray |
| Daiichi Sankyo INC. | $153.30 | 2022-2025 | Enhertu, Injectafer |
| Celgene Corporation | $149.63 | 2022-2024 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $136.20 | 2022-2025 | Keytruda, Lynparza, Lenvima |
| Incyte Corporation | $133.99 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Astellas Pharma US INC | $104.25 | 2023-2024 | Xtandi |
| Exelixis INC. | $99.00 | 2023 | |
| Amgen INC. | $91.02 | 2022-2023 | Kyprolis, Blincyto |
| Lilly USA, LLC | $87.72 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $78.46 | 2023-2025 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $77.38 | 2022-2024 | Fruzaqla, Alunbrig |
| Alexion Pharmaceuticals, INC. | $69.58 | 2022-2024 | Ultomiris |
| Array Biopharma INC | $69.52 | 2024-2025 | Mektovi, Braftovi, Xalkori |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Essendrup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.